Cardiovascular Risk Assessment: Stratification and Management Implications in PV

Opinion
Video

Panelists discuss how thrombotic risk assessment—anchored in age, thrombotic history, and additional factors like leukocytosis and JAK2 allele burden—guides personalized therapy in polycythemia vera (PV), balancing cytoreduction, symptom control, and prevention of vascular events.

Summary for Physicians: Thrombotic Risk Assessment in PV and Its Role in Guiding Therapy

Thrombotic risk assessment is a critical component of therapeutic decision-making in polycythemia vera (PV), as thrombotic events are a leading cause of morbidity and mortality in this disease. Risk stratification is primarily based on clinical factors, but additional markers can further inform treatment strategy.

Key Elements of Risk Assessment:

  • Traditional Risk Factors:

  • Age >60 years

  • History of thrombotic events
    These define the classic high-risk category and are used to guide the initiation of cytoreductive therapy.

  • Additional Considerations:

  • Persistent leukocytosis

  • Cardiovascular comorbidities

  • High JAK2 allele burden
    These factors may influence therapeutic decisions, particularly in patients who fall outside of traditional high-risk definitions but may still carry elevated thrombotic risk.

Impact on Treatment Strategy:

  • Low-Risk Patients (≤60 years, no thrombotic history): Managed with phlebotomy and low-dose aspirin, aiming to maintain hematocrit <45%.

  • High-Risk Patients (>60 years and/or thrombotic history): Require cytoreductive therapy, typically starting with hydroxyurea. Interferons or JAK inhibitors may be considered based on tolerance, adverse effects, and disease features.

The approach emphasizes balancing thrombotic risk reduction with disease control and quality of life, using a tailored strategy based on individual patient characteristics.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content